This HTML5 document contains 65 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n13http://www.rxlist.com/cgi/generic3/
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n23http://linked.opendata.cz/resource/drugbank/drug/DB01056/identifier/pubchem-substance/
foafhttp://xmlns.com/foaf/0.1/
n21http://linked.opendata.cz/resource/drugbank/drug/DB01056/identifier/kegg-drug/
n8http://linked.opendata.cz/resource/mesh/concept/
n22http://linked.opendata.cz/resource/drugbank/drug/DB01056/identifier/drugbank/
n26http://bio2rdf.org/drugbank:
n16http://linked.opendata.cz/resource/drugbank/drug/DB01056/identifier/chemspider/
admshttp://www.w3.org/ns/adms#
n12http://www.drugs.com/mtm/
n14http://linked.opendata.cz/resource/drugbank/drug/DB01056/identifier/chebi/
n6http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
n7http://linked.opendata.cz/ontology/mesh/
n3http://linked.opendata.cz/ontology/drugbank/
n10http://linked.opendata.cz/resource/drugbank/drug/DB01056/identifier/wikipedia/
n4http://linked.opendata.cz/resource/drugbank/property/
n27http://www.pdrhealth.com/drug_info/rxdrugprofiles/drugs/
n24http://linked.opendata.cz/resource/drugbank/drug/DB01056/identifier/pharmgkb/
xsdhhttp://www.w3.org/2001/XMLSchema#
n18http://linked.opendata.cz/resource/drugbank/drug/DB01056/identifier/kegg-compound/
n17http://linked.opendata.cz/resource/drugbank/drug/DB01056/identifier/bindingdb/
n20http://linked.opendata.cz/resource/atc/
n25http://linked.opendata.cz/resource/drugbank/drug/DB01056/identifier/pubchem-compound/
n19http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB01056
rdf:type
n3:Drug
n3:description
An antiarrhythmic agent which exerts a potential- and frequency-dependent block of sodium channels. [PubChem]
n3:group
approved
n3:halfLife
The average plasma half-life in patients is approximately 15 hours. May be prolonged up to 35 hours in patients with severe renal function impairment (creatinine clearance less than 30 mL per min per 1.73 square meters of body surface area.
n3:indication
For the treatment of documented ventricular arrhythmias, such as sustained ventricular tachycardia, that, in the judgment of the physician, are life-threatening.
owl:sameAs
n6:DB01056 n26:DB01056
dcterms:title
Tocainide
adms:identifier
n10:Tocainide n14:9611 n16:35632 n17:50092595 n18:C07142 n21:D06172 n22:DB01056 n23:46505385 n24:PA451706 n25:38945
n3:mechanismOfAction
Tocainide acts on sodium channels on the neuronal cell membrane, limiting the spread of seizure activity and reducing seizure propagation. Tocainide binds preferentially to the inactive state of the sodium channels.The antiarrhythmic actions are mediated through effects on sodium channels in Purkinje fibers.
n3:synonym
Alanyl-2,6-xylidide Tocainidum 2-amino-N-(2,6-Dimethylphenyl)propanamide Tocainida 2-Amino-N-(2,6-dimethylphenyl)propionamid 2-Amino-2',6'-propionoxylidide
n3:toxicity
The oral LD<sub>50</sub> of tocainide was calculated to be about 800 mg/kg in mice, 1000 mg/kg in rats, and 230 mg/kg in guinea pigs; deaths were usually preceded by convulsions.
n3:proteinBinding
Approximately 10 percent bound to plasma protein.
n7:hasConcept
n8:M0025410
foaf:page
n12:tocainide.html n13:tocainide.htm n27:ton1451.shtml
n3:IUPAC-Name
n4:271B5BD9-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B5BDF-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B5BDE-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B5BDB-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B5BDC-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B5BDD-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B5BD7-363D-11E5-9242-09173F13E4C5 n4:271B5BEF-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B5BD5-363D-11E5-9242-09173F13E4C5 n4:271B5BF1-363D-11E5-9242-09173F13E4C5 n4:271B5BD8-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B5BD6-363D-11E5-9242-09173F13E4C5
n19:hasATCCode
n20:C01BB03
n3:H-Bond-Acceptor-Count
n4:271B5BE5-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B5BE6-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B5BE0-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B5BE1-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B5BE3-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B5BE2-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B5BE4-363D-11E5-9242-09173F13E4C5
n3:absorption
Following oral administration, the bioavailability approaches 100 percent, and is unaffected by food.
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
41708-72-9
n3:category
n3:Bioavailability
n4:271B5BEB-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B5BED-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B5BEE-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n4:271B5BF0-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B5BEA-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B5BE9-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B5BEC-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B5BDA-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B5BE7-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B5BE8-363D-11E5-9242-09173F13E4C5